Voclosporin is in Phase III Clinical Development
Voclosporin, an investigational compound, has a synergistic, dual mechanism of action that may have the potential to improve near and long-term outcomes in patients with LN when added to the current standard of care (SoC) of mycophenolate mofetil (MMF) treatment and low oral corticosteroids.
Aurinia has completed a proof of concept study and a Phase 2b clinical study with voclosporin for the treatment of lupus nephritis.
What's a clinical trial?
We have initiated a single, Phase III global placebo-controlled clinical trial to assess voclosporin for the treatment of active lupus nephritis. This study is currently recruiting patients.
AURA-LV - Phase IIb
AURA-LV is the first global clinical trial in active LN to meet its primary endpoint.
We successfully completed AURA-LV (AURA), a global placebo controlled Phase IIb study that aimed to evaluate whether voclosporin added to standard of care can increase speed of remission and overall remission rates in the presence of low doses of steroids.
AURION - Proof of Concept
We successfully completed AURION, an exploratory proof of concept study assessing the short term predictors of remission of Voclosporin 23.7mg BID in combination with standard of care in patients with active lupus nephritis. Patients were evaluated at the exploratory endpoint (8 weeks), then again at 24 weeks and at the end of the study, at 48 weeks.